We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+5.02%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$500M
AUM Growth
-$115M
Cap. Flow
-$85.2M
Cap. Flow %
-17.03%
Top 10 Hldgs %
48.26%
Holding
330
New
47
Increased
56
Reduced
65
Closed
116

Top Buys

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$14.3M
2
IKT icon
Inhibikase Therapeutics
IKT
+$12.7M
3
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$10.1M
4
ABVX
Abivax
ABVX
+$9.13M
5
RVMD icon
Revolution Medicines
RVMD
+$6.34M

Top Sells

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$27.8M
2
CYTK icon
Cytokinetics
CYTK
+$25.8M
3
KROS icon
Keros Therapeutics
KROS
+$21.9M
4
BBIO icon
BridgeBio Pharma
BBIO
+$19.9M
5
ASND icon
Ascendis Pharma A/S
ASND
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.69%
2 Financials 3.07%
3 Communication Services 1.32%
4 Technology 0.33%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MOVE icon
176
Corvex Inc
MOVE
$335M
$103K 0.02%
2,600
-7,900
-75% -$282K
RXRX icon
177
Recursion Pharmaceuticals
RXRX
$1.7B
$101K 0.02%
15,000
– –
NXTC icon
178
NextCure
NXTC
$22.7M
$92.5K 0.02%
10,001
– –
CLYM
179
Climb Bio
CLYM
$802M
$86.6K 0.02%
48,125
-115,318
-71% -$417K
CBIO
180
Crescent Biopharma
CBIO
$610M
$82.6K 0.02%
3,318
+2,861
+626% +$78K
PHAT icon
181
CALL
Phathom Pharmaceuticals
PHAT
$679M
$82K 0.02%
+10,100
New +$125K
ADGM
182
Adagio Medical Holdings
ADGM
$16.3M
$80.6K 0.02%
76,757
-72,104
-48% -$174K
CRVS icon
183
PUT
Corvus Pharmaceuticals
CRVS
$1.17B
$80.3K 0.02%
+15,000
New +$112K
ALLK
184
DELISTED
Allakos
ALLK
$75.3K 0.02%
+62,264
New +$65.4K
CLOV icon
185
Clover Health Investments
CLOV
$2.45B
$73.4K 0.01%
+23,300
New +$83.3K
ELDN icon
186
Eledon Pharmaceuticals
ELDN
$267M
$65.9K 0.01%
+16,000
New +$63.1K
NKTR icon
187
Nektar Therapeutics
NKTR
$2.48B
$63K 0.01%
4,517
– –
PRQR icon
188
ProQR Therapeutics
PRQR
$268M
$54K 0.01%
+20,394
New +$64.8K
CRVS icon
189
CALL
Corvus Pharmaceuticals
CRVS
$1.17B
$53.5K 0.01%
+10,000
New +$74.7K
ACHV icon
190
Achieve Life Sciences
ACHV
$672M
$46.4K 0.01%
13,173
+13,082
+14,376% +$59.3K
ABCL icon
191
AbCellera Biologics
ABCL
$1.99B
$43.9K 0.01%
14,981
-100,000
-87% -$278K
AMLX icon
192
CALL
Amylyx Pharmaceuticals
AMLX
$2.7B
$37.8K 0.01%
10,000
– –
AAM.WS
193
DELISTED
AA Mission Acquisition Corp Warrants
AAM.WS
$35.4K 0.01%
505,099
– –
MREO
194
Mereo BioPharma
MREO
$48.8M
$35K 0.01%
10,000
– –
VERU icon
195
Veru
VERU
$37.1M
$33K 0.01%
5,072
-28
-0.5% -$208
VIGL
196
DELISTED
Vigil Neuroscience
VIGL
$26.4K 0.01%
15,543
-6,194
-28% -$18.3K
GOSS icon
197
CALL
Gossamer Bio
GOSS
$87.2M
$18K ﹤0.01%
19,898
-102
-0.5% -$87
PYXS icon
198
Pyxis Oncology
PYXS
$238M
$15.6K ﹤0.01%
10,000
– –
KPTI icon
199
Karyopharm Therapeutics
KPTI
$44.2M
$13.5K ﹤0.01%
+1,333
New +$16.1K
GLSTR
200
DELISTED
Global Star Acquisition, Inc. Right
GLSTR
$13.3K ﹤0.01%
88,560
– –
6 7
8
9 10

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, ADAR1 Capital Management held 330 positions worth $500M, down 19% from $615M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management withdrew a net $85.2M in Q4 2024, closing 116 positions and reducing 65 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $6.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 86% a quarter earlier, followed by Financials and Communication Services.

Against the trend, ADAR1 Capital Management opened a new position in Inhibikase Therapeutics worth $16.6M.

  • ADAR1 Capital Management's largest Q4 2024 buy was Inhibikase Therapeutics: 5,103,005 shares worth $16.6M.
  • ADAR1 Capital Management added most to Zai Lab in Q4 2024, an estimated $14.3M increase.
  • ADAR1 Capital Management's biggest Q4 2024 reduction was Royalty Pharma, cutting an estimated $27.8M.
  • ADAR1 Capital Management fully exited Syndax Pharmaceuticals in Q4 2024, selling an estimated $6.74M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $500M portfolio in Q4 2024.
  • ADAR1 Capital Management opened 47 new positions and closed 116 in Q4 2024.
  • ADAR1 Capital Management's portfolio value fell 19% quarter-over-quarter to $500M.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.